[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575520":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":80,"locations":35,"responsibleParty":86,"collaborators":90,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":35,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":35,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":115,"whyStopped":35,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":35},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,19],{"label":9,"type":10,"description":11,"interventionNames":12},"sevoflurane group","EXPERIMENTAL","Sevoflurane doses were 0,0.7, 1.0, 1.5, 2.0, 2.5%",[13,14,15,16,17,18],"Drug: Sevoflurane 0 + different doses of ciprofol","Drug: Sevoflurane 0.7% + different doses of ciprofol","Drug: Sevoflurane 1.0% + different doses of ciprofol 0.05","Drug: Sevoflurane 1.5% + differnet doses of ciprofol","Drug: Sevoflurane 2.0% + different doses of ciprofol","Drug: Sevoflurane 2.5% + different doses of ciprofol",{"label":20,"type":10,"description":21,"interventionNames":22},"ciprofol group","The doses of ciprofol were 0, 0.05, 0.1, 0.2, 0.3, 0.4mg\u002Fkg",[23,24,25,26,27,28],"Drug: Ciprofol 0 + different end-expiratory concentration of sevoflurane","Drug: Ciprofol 0.05mg\u002Fkg + different end-expiratory concentration of sevoflurane","Drug: Ciprofol 0.1mg\u002Fkg + different end-expiratory concentration of sevoflurane","Drug: Ciprofol 0.2 mg\u002Fkg + different end-expiratory concentration of sevoflurane","Drug: Ciprofol 0.3 mg\u002Fkg + different end-expiratory concentration of sevoflurane","Drug: Ciprofol 0.4 mg\u002Fkg + different end-expiratory concentration of sevoflurane",[30,36,40,44,48,52,56,60,64,68,72,76],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Sevoflurane 0 + different doses of ciprofol","Sevoflurane 0% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.6mg\u002Fkg, respectively.",[9],null,{"type":31,"name":37,"description":38,"armGroupLabels":39,"otherNames":35},"Sevoflurane 0.7% + different doses of ciprofol","Sevoflurane 0.7% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.5mg\u002Fkg, respectively.",[9],{"type":31,"name":41,"description":42,"armGroupLabels":43,"otherNames":35},"Sevoflurane 1.0% + different doses of ciprofol 0.05","Sevoflurane 1.0% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg\u002Fkg, respectively.",[9],{"type":31,"name":45,"description":46,"armGroupLabels":47,"otherNames":35},"Sevoflurane 1.5% + differnet doses of ciprofol","Sevoflurane 1.5% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg\u002Fkg, respectively.",[9],{"type":31,"name":49,"description":50,"armGroupLabels":51,"otherNames":35},"Sevoflurane 2.0% + different doses of ciprofol","Sevoflurane 2.0% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg\u002Fkg, respectively.",[9],{"type":31,"name":53,"description":54,"armGroupLabels":55,"otherNames":35},"Sevoflurane 2.5% + different doses of ciprofol","Sevoflurane 2.5% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg\u002Fkg, respectively.",[9],{"type":31,"name":57,"description":58,"armGroupLabels":59,"otherNames":35},"Ciprofol 0 + different end-expiratory concentration of sevoflurane","Ciprofol 0 combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5%, respectively.",[20],{"type":31,"name":61,"description":62,"armGroupLabels":63,"otherNames":35},"Ciprofol 0.05mg\u002Fkg + different end-expiratory concentration of sevoflurane","Ciprofol 0.05 mg\u002Fkg combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5 %, respectively.",[20],{"type":31,"name":65,"description":66,"armGroupLabels":67,"otherNames":35},"Ciprofol 0.1mg\u002Fkg + different end-expiratory concentration of sevoflurane","Ciprofol 0.1mg\u002Fkg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.",[20],{"type":31,"name":69,"description":70,"armGroupLabels":71,"otherNames":35},"Ciprofol 0.2 mg\u002Fkg + different end-expiratory concentration of sevoflurane","Ciprofol 0.2 mg\u002Fkg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.",[20],{"type":31,"name":73,"description":74,"armGroupLabels":75,"otherNames":35},"Ciprofol 0.3 mg\u002Fkg + different end-expiratory concentration of sevoflurane","Ciprofol 0.3 mg\u002Fkg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.",[20],{"type":31,"name":77,"description":78,"armGroupLabels":79,"otherNames":35},"Ciprofol 0.4 mg\u002Fkg + different end-expiratory concentration of sevoflurane","Ciprofol 0.4 mg\u002Fkg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.",[20],[81],{"name":82,"role":83,"phone":84,"phoneExt":35,"email":85},"Feng Gao, PhD","CONTACT","+86 13971587381","fgao@tjh.tjmu.edu.cn",{"type":87,"investigatorFullName":88,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"SPONSOR_INVESTIGATOR","Feng Gao","Professor",[91],{"name":92,"class":6},"Sichuan Provincial People's Hospital","100575520","phase-4-a-response-surface-analysis-for-the-interaction-between-ciprofol-and-sevoflurane-100575520",false,"NCT06773351","A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane","A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane During Anesthesia Induction","Inclusion Criteria:\n\n* Patients undergoing elective general anesthesia and non-cardiac surgery;\n* Age 18-60 years old, gender is not limited;\n* ASA I or II level;\n* Body mass index (BMI) 18-30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Preoperative assessment of potential difficult airway risk;\n* Airway hyperreactivity;\n* There is disease of the central nervous system or cardiovascular system;\n* Currently using drugs that may alter the pharmacokinetics and pharmacokinetics of the drug under study;\n* Known or suspected allergy or contraindication to the components or regimens of the investigational drug;\n* A history of drug or alcohol addiction;\n* Patients with gastroesophageal reflux disease;\n* Severe liver and kidney dysfunction.","ALL","18 Years","60 Years",{"count":104,"type":105},300,"ESTIMATED","INTERVENTIONAL",[108],"PHASE4","Intravenous and inhalation combined anesthesia is a commonly used method for maintaining general anesthesia in clinical practice. This study aims to explore the interaction between ciprofol and sevoflurane. By employing response surface methodology, we constructed a three-dimensional pharmacodynamic interaction surface for various dose combinations of ciprofol and sevoflurane. This approach allows us to determine the nature of the interaction between the two drugs at any given level, thereby providing a ciprofol understanding of the dose-response relationship when ciprofol and sevoflurane are used in combination. This knowledge will serve as a theoretical basis for rational drug administration during surgery.",[111],"Induction of General Anesthesia",[113,114],"ciprofol","response surface analysis","NOT_YET_RECRUITING","2025-01-13",{"date":118,"type":119},"2025-01-14","ACTUAL",{"date":121,"type":105},"2025-02-01",{"date":123,"type":105},"2025-12-31",{"name":88,"class":6}]